|
|
生物可吸收血管支架在冠心病患者中的应用研究进展
|
Abstract:
生物可吸收血管支架(Bioresorbable vascular scaffold, BVS)是一种新型的支架装置，它提供结构支持和药物释放，以防止早期反冲或再狭窄，然后降解为无毒化合物。可以避免与金属药物洗脱支架(drug-eluting stents, DESs)相关的晚期并发症。虽然BVS在冠心病患者中应用的优势性已被公认。然而，有研究表明使用BVS时，支架内血栓的发生率也较高，引起了临床广泛关注。因此，为了说明BVS的安全性和有效性，本研究采用文献综述的方法，对国内外生物可吸收血管支架在冠心病患者中的应用研究进展进行综述，以期为临床冠心病缓则支架的选择和相关研究提供借鉴。
Bioresorbable vascular scaffold (BVS) is a novel scaffold device that provides structural support and drug release to prevent early recoil or restenosis and then degrades into non-toxic compounds. Late complications associated with metal drug-eluting stents (DESs) can be avoided. Although BVS has been recognized for their superiority in patients with coronary heart disease, however, some stud-ies have shown that the incidence of stent thrombosis is also high when using BVS, which has aroused widespread clinical concern. Therefore, in order to illustrate the safety and effectiveness of BVS, this study adopts the method of literature review to review the research progress in the appli-cation of bioabsorbable vascular stents in patients with coronary heart disease at home and abroad, in order to provide references for the selection of stents in patients with chronic coronary heart disease and related studies.
| [1] | Kondo, T., Nakano, Y., Adachi, S. and Murohara, T. (2019) Effects of Tobacco Smoking on Cardiovascular Disease. Circulation Journal, 83, 1980-1985. https://doi.org/10.1253/circj.CJ-19-0323 |
| [2] | 基层冠心病与缺血性脑卒中共患管理专家共识2022 [J]. 心脑血管病防治, 2022, 22(4): 1-19. |
| [3] | 贾薇薇. 2022年我国心血管领域十部指南权威解读[N]. 医师报, 2022-12-29(B04). |
| [4] | 梁燕, 张亮, 付莹, 等. 冠心病患者PCI术后支架内再狭窄的危险因素分析[J]. 医疗装备, 2023, 36(5): 119-121. |
| [5] | 许胜胜, 庞玉琦, 刘剑雄. 药物涂层球囊在冠状动脉分叉病变中的应用研究进展[J]. 西部医学, 2023, 35(3): 466-468. |
| [6] | 刘彬彬. 不同类型的冠心病患者实施支架植入术与p-选择素、hsCRP及预后的相关性分析[J]. 中国医疗器械信息, 2019, 25(16): 44-45. |
| [7] | 黄艳, 马乐娟, 季建琴, 等. 围术期肺部感染PCI冠心病患者术后6个月MACE危险因素及其预测模型[J].中华医院感染学杂志, 2023(8): 1207-1211. |
| [8] | 戴敬, 吕树铮, 宋现涛, 等. 冠心病合并糖尿病患者经皮冠状动脉介入治疗中的支架选择和远期预后[J]. 中华老年心脑血管病杂志, 2016, 18(12): 1325-1327. |
| [9] | 朱博, 袁宏伟, 石宇奇, 等. 中西医预防冠脉支架术后再狭窄的临床研究进展[J]. 内蒙古中医药, 2020, 39(2): 151-153. |
| [10] | Pahmeier, K., Neusser, S., Hamm, C., et al., for the GABI-R Study Group (2022) Quality of life of Patients with Coronary Heart Disease Treated with the Bioresorbable Vascular Scaffold (ABSORB？): 2-Year Results from the GABI-R-Registry. BMC Cardiovascular Dis-orders, 22, Article No. 379. https://doi.org/10.1186/s12872-022-02815-2 |
| [11] | Stone, G.W., Maehara, A., Ali, Z.A., et al., PROSPECT ABSORB Investigators (2020) Percutaneous Coronary Intervention for Vulnerable Coronary Ather-osclerotic Plaque. Journal of the American College of Cardiology, 76, 2289-2301. https://doi.org/10.1016/j.jacc.2020.09.547 |
| [12] | Chhabra, L., Zain, M.A. and Siddiqui, W.J. (2023) Coronary Stents. StatPearls Publishing, Tampa. |
| [13] | Masiero, G., Rodinò, G., Matsuda, J., et al. (2020) Bioresorbable Coronary Scaf-fold Technologies: What’s New? Giuseppe Tarantini, 38, 589-599. https://doi.org/10.1016/j.ccl.2020.07.004 |
| [14] | Lee, S.Y., Kang, D.Y., Hong, S.J., et al. (2020) Optical Coherence Tomography for Coronary Bioresorbable Vascular Scaffold Implantation: A Randomized Controlled Trial. Circulation: Cardiovascular Interventions, 13, e008383.
https://doi.org/10.1161/CIRCINTERVENTIONS.119.008383 |
| [15] | Alfonso, F., Cuesta, J. and Rivero, F. (2021) Coronary Bioresorbable Vascular Scaffolds: Requiescant in Pace? Revista Espa？ola de Cardiología (English Edition), 74, 569-572. https://doi.org/10.1016/j.rec.2020.11.018 |
| [16] | Serruys, P.W., Onuma, Y., Dudek, D., et al. (2011) Eval-uation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes. Journal of the American College of Cardiology, 58, 1578-1588.
https://doi.org/10.1016/j.jacc.2011.05.050 |
| [17] | Serruys, P.W., Onuma, Y., Ormiston, J.A., et al. (2010) Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes. Circulation, 122, 2301-2312. https://doi.org/10.1161/CIRCULATIONAHA.110.970772 |
| [18] | Onuma, Y., Serruys, P.W., Gomez, J., et al., on Behalf of the ABSORB Cohort A and B Investigators (2011) Comparison of in Vivo Acute Stent Recoil between the Bi-oresorbable Everolimus-Eluting Coronary Scaffolds (Revision 1.0 and 1.1) and the Metallic Everolimus-Eluting Stent. Catheterization and Cardiovascular Interventions, 78, 3-12.
https://doi.org/10.1002/ccd.22864 |
| [19] | Serruys, P.W., Chevalier, B., Dudek, D., Cequier, A., et al. (2015) A Bio-resorbable Everolimus-Eluting Scaffold versus a Metallic Everolimus-Eluting Stent for Ischaemic Heart Disease Caused by De-Novo Native Coronary Artery Lesions (ABSORB II): An Interim 1-Year Analysis of Clinical and Procedural Secondary Outcomes from a Randomised Controlled Trial. The Lancet, 385, 43-54. https://doi.org/10.1016/S0140-6736(14)61455-0 |
| [20] | Oberhauser, J.P., Hossainy, S. and Rapoza, R.J. (2009) De-sign Principles and Performance of Bioresorbable Polymeric Vascular Scaffolds. EuroIntervention, 5, F15-F22. https://doi.org/10.4244/EIJV5IFA3 |
| [21] | Ormiston, J., Webster, M. and Armstrong, G. (2007) First-in-Human Im-plantation of a Fully Bioabsorbable Drug-Eluting Stent: the BVS Poly-L-Lactic Acid Everolimus-Eluting Coronary Stent. Catheterization and Cardiovascular Interventions, 69, 128-131. https://doi.org/10.1002/ccd.20895 |
| [22] | Azzalini, L., Ellis, S.G., Kereiakes, D.J., et al. (2021) Optimal Dual Antiplatelet Therapy Duration for Bioresorbable Scaffolds: An Individual Patient Data Pooled Analysis of the ABSORB Trials. EuroIntervention, 17, e981-e988.
https://doi.org/10.4244/EIJ-D-21-00263 |
| [23] | Abizaid, A., Costa, J.R., Bartorelli, A.L., et al. (2015) The ABSORB EXTEND Study: Preliminary Report of the Twelve-Month Clinical Outcomes in the First 512 Patients Enrolled. EuroIn-tervention, 10, 1396-1401.
https://doi.org/10.4244/EIJV10I12A243 |
| [24] | Grube, E., Chevalier, B., Smits, P., et al., SPIRIT V Investigators (2011) The SPIRIT V Study: A Clinical Evaluation of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients with De Novo Coronary Artery Lesions. JACC: Cardiovascular Interventions, 4, 168-175. https://doi.org/10.1016/j.jcin.2010.11.006 |
| [25] | Suwannasom, P., Sotomi, Y., Ishibashi, Y., et al. (2016) The Im-pact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Me-tallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. JACC: Cardiovascular Interventions, 9, 1231-1242.
https://doi.org/10.1016/j.jcin.2016.03.027 |
| [26] | Schukraft, S., Arroyo, D., Togni, M., et al. (2022) Five-Year An-giographic, OCT and Clinical Outcomes of a Randomized Comparison of Everolimus and Biolimus-Eluting Coronary Stents with Everolimus-Eluting Bioresorbable Vascular Scaffolds. Catheterization and Cardiovascular Interventions, 99, 523-532. https://doi.org/10.1002/ccd.29837 |
| [27] | Généreux, P., Rutledge, D.R., Palmerini, T., et al. (2015) Stent Thrombosis and Dual Antiplatelet Therapy Interruption with Everolimus-Eluting Stents: Insights from the Xience V Coronary Stent System Trials. Circulation: Cardiovascular Interventions, 8, e001362. https://doi.org/10.1161/CIRCINTERVENTIONS.114.001362 |
| [28] | Serruys, P.W., Onuma, Y., Garcia-Garcia, H.M., et al. (2014) Dynamics of Vessel Wall Changes Following the Implantation of the Absorb Everolimus-Eluting Bi-oresorbable Vascular Scaffold: A Multi-Imaging Modality Study at 6, 12, 24 and 36 Months. EuroIntervention, 9, 1271-1284. https://doi.org/10.4244/EIJV9I11A217 |
| [29] | Murthy, V.L., Naya, M., Foster, C.R., et al. (2011) Im-proved Cardiac Risk Assessment with Noninvasive Measures of Coronary Flow Reserve. Circulation, 124, 2215-2224. https://doi.org/10.1161/CIRCULATIONAHA.111.050427 |
| [30] | Gould, K.L., Johnson, N.P., Bateman, T.M., et al. (2013) Anatomic versus Physiologic Assessment of Coronary Artery disease: Role of Coronary Flow Reserve, Fraction-al Flow Reserve and Positron Emission Tomography Imaging in Revascularization Decision-Making. Journal of the American College of Cardiology, 62, 1639-1653.
https://doi.org/10.1016/j.jacc.2013.07.076 |
| [31] | Onuma, Y., Dudek, D., Thuesen, L., et al. (2013) Five-Year Clini-cal and Functional Multislice Computed Tomography Angiographic Results after Coronary Implantation of the Fully Re-sorbable Polymeric Everolimus-Eluting Scaffold in Patients with De Novo Coronary Artery Disease: The ABSORB Cohort A Trial. JACC: Cardiovascular Interventions, 6, 999-1009. https://doi.org/10.1016/j.jcin.2013.05.017 |
| [32] | Bourantas, C.V., Serruys, P.W., Nakatani, S., et al. (2014) Biore-sorbable Vascular Scaffold Treatment Induces the Formation of Neointimal Cap that Seals the Underlying Plaque without Compromising the Luminal Dimensions: A Concept Based on Serial Optical Coherence Tomography Data. EuroInter-vention, 11, 746-756. |
| [33] | Brugaletta, S., Radu, M.D., Garcia-Garcia, H.M., et al. (2012) Circumferential Evaluation of the Neointima by Optical Coherence Tomography after ABSORB Bioresorbable Vascular Scaffold Implantation: Can the Scaffold Cap the Plaque? Atherosclerosis, 221, 106-112. https://doi.org/10.1016/j.atherosclerosis.2011.12.008 |
| [34] | 许浩博, 乔树宾, 袁建松, 等. 药物洗脱支架联合药物涂层球囊治疗原位冠状动脉弥漫病变的初步分析[J]. 中国循环杂志, 2023, 38(2): 146-151. |
| [35] | 送江？吾斯曼, 马热亚？吾布力, 尼加提江？米孜, 等. 药物涂层球囊与药物洗脱支架治疗冠状动脉原发病变安全性和短期预后的比较[J]. 中国医药, 2022, 17(12): 1766-1771. |
| [36] | 班雷. 药物涂层支架在冠心病介入治疗中的应用疗效及不良事件发生率分析[J]. 中国医疗器械信息, 2022, 28(22): 74-76. |
| [37] | Fan, W., Tan, J., Li, L., et al. (2022) Efficacy and Safety of Absorb Everolimus-Eluting Bioresorbable Vas-cular Scaffold in Peripheral Artery Disease: A Single-Arm Meta-Analysis. Journal of Endovascular Therapy.
https://doi.org/10.1016/j.atherosclerosis.2011.12.008 |
| [38] | Rola, P., W？odarczak, S., Doroszko, A., Lesiak, M. and W？odarczak, A. (2022) The Bioresorbable Magnesium Scaffold (Magmaris)—State of the Art: From Basic Concept to Clinical Application. Catheterization and Cardiovascular Interventions, 100, 1051-1058. https://doi.org/10.1002/ccd.30435 |
| [39] | Erglis, A., Narbute, I, Sondore, D., et al. (2022) Four-Year Outcomes of Left Main Percutaneous Coronary Intervention with a Bioresorbable Scaffold in the Circumflex Ostium. Journal of In-terventional Cardiology, 2022, Article ID: 7934868. https://doi.org/10.1155/2022/7934868 |
